Biocon Biologics India Limited

Biocon Biologics India Limited, a subsidiary of Biocon Limited, is a global leader in the development and commercialization of high-quality, affordable biosimilars. Established on June 8, 2016, with Corporate Identification Number (CIN) U24119KA2016FLC093936, the company is headquartered in Bengaluru, Karnataka, India. Biocon Limited, the parent company, is a publicly listed biopharmaceutical enterprise founded in 1978 by Kiran Mazumdar-Shaw. Biocon Biologics operates as an independent entity with its own dedicated management, focusing on biosimilars across therapeutic areas such as diabetes, oncology, and immunology.

As of March 2023, Biocon Limited employed approximately 16,545 individuals, reflecting its expansive operations and commitment to innovation in the biopharmaceutical sector. The company's official website, www.bioconbiologics.com, provides comprehensive information about its products, services, and corporate initiatives.

Biocon Biologics operates state-of-the-art manufacturing facilities in Bengaluru, India, and Johor, Malaysia, designed to meet stringent cGMP guidelines and international regulatory standards. These facilities encompass large-scale microbial fermentation, mammalian cell culture, protein and antibody purification, aseptic formulation, and fill-finish processes. The Bengaluru campus, spanning approximately 90 acres, is approved by regulatory agencies such as the USFDA, EMA, COFEPRIS, and KFDA, and specializes in APIs derived from fermentation, synthetic chemistry, peptides, HPAPIs, and oral solid formulations. The Johor facility further extends Biocon Biologics' global manufacturing capabilities, supporting its expansive biosimilars portfolio.

Biocon Biologics is led by a team of seasoned professionals committed to advancing the company's mission. Shreehas P. Tambe serves as the Chief Executive Officer and Managing Director, overseeing the company's strategic direction and operations. Siddharth Mittal, the CEO and Managing Director of Biocon Limited, provides overarching leadership to the group. Kiran Mazumdar-Shaw, the Executive Chairperson of Biocon Limited, offers strategic guidance and vision. Peter Bains, the Group CEO, brings extensive experience in the biopharmaceutical industry, contributing to the company's global expansion and innovation initiatives.

Biocon Biologics has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has commercialized multiple biosimilars in these regions, such as Trastuzumab, Pegfilgrastim, Bevacizumab, recombinant human Insulin, and Insulin Glargine. In May 2024, Biocon Biologics received FDA approval for its first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar of aflibercept. This approval underscores the company's commitment to expanding access to affordable biologic therapies in advanced markets.

Biocon Biologics has made significant inroads into emerging markets, including Africa, Latin America, and Southeast Asia. The company's portfolio of biosimilars has been commercialized in over 100 countries, addressing the healthcare needs of diverse populations. The World Health Organization's prequalification of Biocon Biologics' products has facilitated access to these markets, ensuring that patients benefit from high-quality, affordable biosimilars.

Biocon Biologics' geographic strategy demonstrates a balanced approach, with a strong presence in both developed and emerging markets. The company's focus on biosimilars allows it to address unmet medical needs across a wide range of therapeutic areas, including diabetes, oncology, and immunology. By leveraging its manufacturing capabilities and regulatory approvals, Biocon Biologics mitigates concentration risk and positions itself for sustainable growth in diverse markets.

Biocon Biologics has achieved significant milestones with the U.S. Food and Drug Administration (FDA). The company has received approvals for multiple biosimilars, including Trastuzumab, Pegfilgrastim, and Insulin Glargine. In May 2024, Biocon Biologics received FDA approval for its first-to-file application for Yesafili™ (aflibercept-jbvf), an interchangeable biosimilar of aflibercept. These approvals reflect the company's commitment to meeting the rigorous standards set by the FDA and expanding access to affordable biologic therapies in the U.S. market.

Biocon Biologics' manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's facilities in Bengaluru, India, and Johor, Malaysia, are designed to meet stringent cGMP guidelines and comply with international regulatory standards. These certifications ensure that Biocon Biologics' products meet the highest quality standards, facilitating access to global markets.

In India, Biocon Biologics operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company's manufacturing facilities in Bengaluru, Hyderabad, and Visakhapatnam are approved by the CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing. These approvals underscore Biocon Biologics' commitment to maintaining high-quality manufacturing practices in its home market.

As of March 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued by the FDA or other regulatory bodies concerning Biocon Biologics. The company's adherence to stringent cGMP guidelines and international regulatory standards reflects its commitment to quality and compliance.

Biocon Biologics operates in a competitive landscape with several key players in the biosimilars market. Notable competitors include Sandoz, Celltrion, and Samsung Bioepis, which also offer biosimilars across various therapeutic areas. Biocon Biologics differentiates itself through its expansive portfolio, including recombinant human Insulin, Insulin Glargine, Trastuzumab, and Pegfilgrastim, and its global manufacturing capabilities. The company's strategic focus on affordability and access positions it favorably in the global biosimilars market.

Biocon Biologics' key differentiators include its fully integrated biosimilars portfolio, spanning insulins, monoclonal antibodies, and conjugated recombinant proteins. The company's manufacturing facilities in Bengaluru, India, and Johor, Malaysia, are designed to meet stringent cGMP guidelines and comply with international regulatory standards. Additionally, Biocon Biologics' commitment to affordability and access to healthcare solutions sets it apart in the biopharmaceutical industry.

Biocon Biologics' strategic direction focuses on the development and commercialization of biosimilars, aiming to expand access to affordable biologic therapies globally. The company's recent acquisition of the global biosimilars business of Viatris for over USD 3 billion in cash and stock has positioned it as a leading global biosimilars enterprise. This acquisition enhances Biocon Biologics' capabilities in research and development, manufacturing, and commercialization, supporting its mission to transform patient lives through innovative and inclusive healthcare solutions.

Biocon Biologics has a strong track record in the biopharmaceutical industry, with a focus on developing high-quality, affordable biosimilars. The company's manufacturing facilities in Bengaluru, India, and Johor, Malaysia, are designed to meet stringent cGMP guidelines and comply with international regulatory standards. Biocon Biologics' commitment to quality and compliance, along with its expansive portfolio and global manufacturing capabilities, make it a reliable supplier in the biosimilars market.